Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/21
Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021GlobeNewsWire • 05/14/21
Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific TimeGlobeNewsWire • 05/11/21
Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021GlobeNewsWire • 04/30/21
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access PathwayGlobeNewsWire • 04/08/21
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/31/21
Physician-Scientist Steven Quay Provides Open Letter Response to WHO Report: Five Undisputed Facts Support the Laboratory Origin of the COVID VirusPRNewsWire • 03/30/21
Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 03/22/21
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access PathwayGlobeNewsWire • 03/11/21
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021GlobeNewsWire • 02/10/21
ATOS Stock: 8 Things for Investors to Know About Atossa Therapeutics as It Soars ThursdayInvestorPlace • 02/04/21
Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with EndoxifenGlobeNewsWire • 02/03/21
Atossa Therapeutics' Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted EarlyGlobeNewsWire • 02/02/21
Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding WarrantsGlobeNewsWire • 01/29/21
